The purpose of this study is to determine whether moxidectin (Mox) will be more effective
than ivermectin (IVM) when used in single-dose combination therapies for lymphatic filariasis
(LF).
Phase:
Phase 3
Details
Lead Sponsor:
Washington University School of Medicine
Collaborators:
Case Western Reserve University Regional Hospital of Agboville, Southern Cote d'Ivoire